Utilization of glucose, blood pressure, and lipid lowering medications among people with type II diabetes in the United States, 1999-2010

Annals of Epidemiology

Volumn 24, Issue 7, 2014, Pages

  Wong, Hoi Kin ^a   Ong, Kwok Leung ^b,c   Cheung, Ching Lung ^a   Cheung, Bernard M Y ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c University of Sydney   (Australia)

Author keywords

Diabetes; NHANES; Prescription medications

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BILE ACID SEQUESTRANT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; NICOTINIC ACID; SULFONYLUREA DERIVATIVE; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; PRESCRIPTION DRUG;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEALTH SURVEY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; UNITED STATES; YOUNG ADULT; AGED; ANALYSIS; BLOOD; BLOOD PRESSURE; CLINICAL PRACTICE; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; DYSLIPIDEMIAS; NUTRITION; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; NUTRITION SURVEYS; OUTCOME ASSESSMENT (HEALTH CARE); PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTION DRUGS; QUESTIONNAIRES; UNITED STATES;

EID: 84902511449     PISSN: 10472797     EISSN: 18732585     Source Type: Journal    
DOI: 10.1016/j.annepidem.2014.05.001     Document Type: Article

References (30)

1. The Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States;2011.
2. Cheung B.M., Ong K.L., Cherny S.S., Sham P.C., Tso A.W., Lam K.S. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med 2009, 122:443-453.
3. Patel A., MacMahon S., Chalmers J., Neal B., Billot L., Woodward M., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. NEngl J Med 2008, 358:2560-2572. ADVANCE Collaborative Group.
4. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998, 317:703-713.
5. Gross J.L., de Azevedo M.J., Silveiro S.P., Canani L.H., Caramori M.L., Zelmanovitz T., et al. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 2005, 28:164-176.
6. Ong K.L., Cheung B.M., Wong L.Y., Wat N.M., Tan K.C., Lam K.S., et al. Prevalence, treatment, and control of diagnosed diabetes in the U.S. National Health and Nutrition Examination Survey 1999-2004. Ann Epidemiol 2008, 18:222-229.
7. Ali M.K., Bullard K.M., Saaddine J.B., Cowie C.C., Imperatore G., Gregg E.W. Achievement of goals in U.S. diabetes care, 1999-2010. NEngl J Med 2013, 368:1613-1624.
8. Alexander G.C., Sehgal N.L., Moloney R.M., Stafford R.S. National trends in treatment of type 2 diabetes mellitus, 1994-2007. Arch Intern Med 2008, 168:2088-2094.
9. Cox M.E., Feinglos M.N. Risk vs benefit in diabetes pharmacotherapy: a rational approach to choosing pharmacotherapy in type 2 diabetes. Curr Diab Rep 2013, 13:319-328.
10. National Health and Nutrition Examination Survey 1999-2010 questionnaires, datasets, and related documentation 2012, National Center for Health Statistics, Centers for Disease Control and Prevention, Hyattsville, MD, Available at. http://www.cdc.gov/nchs/nhanes.htm.
11. Koopman R.J., Mainous A.G., Diaz V.A., Geesey M.E. Changes in age at diagnosis of type 2 diabetes mellitus in the United States, 1988 to 2000. Ann Fam Med 2005, 3:60-63.
12. Li M., Ong K.L., Tse H.F., Cheung B.M. Utilization of lipid lowering medications among adults in the United States 1999-2006. Atherosclerosis 2010, 208:456-460.
13. Ong K.L., Allison M.A., Cheung B.M., Wu B.J., Barter P.J., Rye K.A. Trends in C-reactive protein levels in United States adults from 1999 to 2010. Am J Epidemiol 2013, 177:1430-1442.
14. Ong K.L., Wu B.J., Cheung B.M., Barter B.J., Rye K.A. Association of lower total bilirubin level with statin usage: the United States National Health and Nutrition Examination Survey 1999-2008. Atherosclerosis 2011, 219:728-733.
15. Ong K.L., Wu B.J., Cheung B.M., Barter P.J., Rye K.A. Arthritis: its prevalence, risk factors, and association with cardiovascular diseases in the United States, 1999 to 2008. Ann Epidemiol 2013, 23:80-86.
16. Standards of medical care in diabetes- 2013. Diabetes Care 2013, 36(Suppl 1):S11-S66. American Diabetes Association.
17. The Centers for Disease Control and Prevention. The National Health and Nutrition Examination Survey (NHANES) Analytic and Reporting Guidelines. Available at: Accessed June 12,2013. http://www.cdc.gov/nchs/data/nhanes/nhanes_03_04/nhanes_analytic_guidelines_dec_2005.pdf.
18. Selvin E., Parrinello C.M., Sacks D.B., Coresh J. Trends in prevalence and control of diabetes in the United States, 1988-1994 and 1999-2010. Ann Intern Med 2014, 160:517-525.
19. Gregg E.W., Li Y., Wang J., Burrows N.R., Ali M.K., Rolka D., et al. Changes in diabetes-related complications in the United States, 1990-2010. NEngl J Med 2014, 370:1514-1523.
20. Currie C.J., Poole C.D., Jenkins-Jones S., Gale E.A., Johnson J.A., Morgan C.L. Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care 2012, 35:299-304.
21. Graham D.J., Ouellet-Hellstrom R., MaCurdy T.E., Ali F., Sholley C., Worrall C., et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010, 304:411-418.
22. Juurlink D.N., Gomes T., Lipscombe L.L., Austin P.C., Hux J.E., Mamdani M.M. Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. BMJ 2009, 339:b2942.
23. Bennett W.L., Maruthur N.M., Singh S., Segal J.B., Wilson L.M., Chatterjee R., et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 2011, 154:602-613.
24. Cox M.E., Rowell J., Corsino L., Green J.B. Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy. Drug Healthc Patient Saf 2010, 2:7-19.
25. Cooper-DeHoff R.M., Pacanowski M.A., Pepine C.J. Cardiovascular therapies and associated glucose homeostasis: implications across the dysglycemia continuum. JAm Coll Cardiol 2009, 53(5 Suppl):S28-S34.
26. Moser M. Is new-onset diabetes of clinical significance in treated hypertensive patients?. Con J Clin Hypertens (Greenwich) 2006, 8:126-132.
27. Karnes J.H., Cooper-DeHoff R.M. Antihypertensive medications: benefits of blood pressure lowering and hazards of metabolic effects. Expert Rev Cardiovasc Ther 2009, 7:689-702.
28. Waters D.D., Ho J.E., Boekholdt S.M., DeMicco D.A., Kastelein J.J., Messig M., et al. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes. JAm Coll Cardiol 2013, 61:148-152.
29. Kennedy R.L., Vangaveti V., Malabu U.H. Statin treatment and diabetes. JAm Coll Cardiol 2013, 61:1933-1934.
30. Bellia A., Rizza S., Lombardo M.F., Donadel G., Fabiano R., Andreadi K., et al. Deterioration of glucose homeostasis in type 2 diabetic patients one year after beginning of statins therapy. Atherosclerosis 2012, 223:197-203.